三阴性乳腺癌（TNBC）表现出早期复发和转移的倾向。此外，在使用阿霉素、紫杉醇、多西他赛和顺铂等药物进行化疗后几个月，往往会出现耐药性。 miR-200 家族和 miR-205 被认为是转移的关键调节因子，通过抑制 ZEB1 来调节上皮间质转化 (EMT)。因此，这些 microRNA 可能提供治疗应用。此外，它们具有抑制化疗耐药性和增加化疗敏感性的潜力。这些 microRNA 在 TNBC 细胞中受到抑制。然而，增加它们的水平可以抑制 EMT 并提高无进展生存期 (PFS)。除了通过病毒载体使用直接 miRNA 疗法外，一些药物（如对乙酰氨基酚或他莫昔芬）由于能够上调这些 miRNA，因此被认为对 TNBC 有用。在这篇综述中，通过对 PubMed、Embase 和 Medline 进行高级检索并选择相关研究，我们旨在探索这些 microRNA 在控制 EMT 和克服化疗耐药方面的潜在应用。版权所有 © 2024 作者。由 Elsevier B.V. 出版。保留所有权利。

Triple-negative breast cancer (TNBC) exhibits a proclivity for early recurrence and development of metastasis. Moreover, drug resistance tends to arise few months following chemotherapeutic regimen with agents such as Doxorubicin, Paclitaxel, Docetaxel, and Cisplatin. miR-200 family and miR-205 are considered key regulators of metastasis by regulating the Epithelial-to-mesenchymal transition (EMT) via inhibiting ZEB1. Therefore, these microRNAs may offer therapeutic applications. Moreover, they hold potential for inhibiting chemoresistance and increasing chemosensitivity. These microRNAs are suppressed in TNBC cells. Increasing their levels, however, can inhibit EMT and improve progression-free survival (PFS). Besides using direct miRNA therapy via viral vectors, some drugs like Acetaminophen, or Tamoxifen are deemed useful for TNBC due to their ability to upregulate these miRNAs. In this review, by conducting an advanced search on PubMed, Embase, and Medline and selecting pertinent studies, we aimed to explore the potential applications of these microRNAs in controlling EMT and overcoming chemoresistance.Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.